In this lecture, we will look at most recent promising results with CAR-T cells in solid tumor patients. In addition, also T cell receptor (TCR) modified T cell and tumor infiltrating lymphocyte (TIL) therapy results will be discussed. Especially TIL therapy recently showed in a randomized phase III trial higher response rates compared to immune checkpoint inhibitor treatment in patients with metastatic melanoma. Finally, we discuss different future strategies to potentially overcome the resistance of solid tumors to T cell therapy.
What is Cancer Core Europe (CCE)?
Cancer Core Europe is a consortium of seven leading cancer centers. CCEs members are driven by a strong will to reshape the cancer research model to ultimately increase the European Union’s competitiveness as a place to conduct cutting-edge research that’s translated to the clinic to deliver more personalized medicine.
What is the content and aim of the CCE Lecture?
The CCE Lecture series is a CCE-internal event, which educates and informs about state-of-the-art research within the seven centers and is aimed to increase awareness among partners about each other’s activities and potential for collaboration.